NCT01749514View on ClinicalTrials.gov

Study of Luspatercept for the Treatment of Anemia in Patients With Myelodysplastic Syndrome (MDS) (MK-6143-001)

PHASE2CompletedINTERVENTIONAL

Enrollment

116

Participants

Timeline

Start Date

January 21, 2013

Primary Completion Date

October 22, 2018

Study Completion Date

October 22, 2018

Conditions

Anemia

Interventions

DRUG

Luspatercept

Participants receive luspatercept up to 1.75mg/kg subcutaneously (SC) every 3 weeks for up to 5 cycles (each cycle length = 21 days).

Trial Locations (1)

Unknown

Acceleron Investigative Site, Dresden

All Listed Sponsors

lead

Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA

INDUSTRY

NCT01749514 - Study of Luspatercept for the Treatment of Anemia in Patients With Myelodysplastic Syndrome (MDS) (MK-6143-001) | Biotech Hunter | Biotech Hunter